- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Elutia Flat on Sale to Cellution | 1 | Baystreet.ca | ||
| 18.08. | Elutia sells SimpliDerm business for up to $11 million | 2 | Investing.com | ||
| 18.08. | Elutia Inc.: Elutia Completes SimpliDerm Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch | 3 | GlobeNewswire (USA) | ||
| 14.08. | ELUTIA INC. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 14.08. | Elutia anticipates NXT-41x clearance in 1H 2027 while targeting >80% gross margins at scale | 1 | Seeking Alpha | ||
| 14.08. | Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch | 1 | Investing.com | ||
| 14.08. | Elutia Q2 2026 Earnings Call Transcript | 1 | Benzinga.com | ||
| ELUTIA Aktie jetzt für 0€ handeln | |||||
| 13.08. | Elutia GAAP EPS of -$0.17 misses by $0.02, revenue of $2.4M misses by $0.5M | 1 | Seeking Alpha | ||
| 13.08. | Elutia sichert sich 26 Mio. USD Kapital vor wichtiger FDA-Entscheidung | 2 | Investing.com Deutsch | ||
| 13.08. | Elutia secures $26M in capital, expects FDA decision on NXT-41 | 1 | Investing.com | ||
| 13.08. | Elutia secures $15 million financing for product development | 1 | Investing.com | ||
| 13.08. | Elutia Inc.: Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results | 177 | GlobeNewswire (Europe) | Funded through launch: secured up to $26 million of capital without an equity offeringThe unmet need is real: 86% of surgeons surveyed say the matrices they use today increase infection riskThe demand... ► Artikel lesen | |
| 07.08. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 31.07. | Elutia Inc.: Elutia to Report Second Quarter 2026 Financial Results on Thursday, August 13, 2026 | 1 | GlobeNewswire (USA) | ||
| 20.07. | ELUTIA INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.07. | Elutia Sheds Legacy Business to Chase $1.5 Billion Market Opportunity | 3 | Benzinga.com | ||
| 17.07. | Elutia To Divest SimpliDerm Business For Up to $11 Million | 1 | pulse2.com | ||
| 16.07. | Elutia to sell SimpliDerm business for up to $11 million | 1 | Investing.com | ||
| 16.07. | Elutia Inc.: Elutia Signs Definitive Agreement to Sell SimpliDerm in Transaction Valued at up to $11 Million, Strengthening Balance Sheet Ahead of NXT-41x Launch | 160 | GlobeNewswire (Europe) | Transaction provides $8 million in cash at closing and up to $3 million in technology transfer and commercial milestone payments over the next 18 monthsProceeds provide additional non-dilutive capital... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern |
Das Unternehmen ELUTIA INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.